
Frontier Medicines is seeking a highly motivated Scientist, Cheminformatics AI to join our Machine Learning organization. This role will play a key scientific and technical role in advancing Frontier’s AI and cheminformatics capabilities in support of covalent small molecule drug discovery.
The successful candidate will design and implement machine learning, cheminformatics, and advanced analytics workflows that leverage Frontier’s large scale covalent chemistry data to guide covalent compound design, prioritization, and optimization. This role works closely with medicinal chemistry, biology, and cross-functional drug discovery teams to translate complex data into actionable insights.
This position is ideal for an individual contributor who thrives in scientifically uncharted territory and enjoys building novel solutions where no template exists and loves to enable others through their work.
This is an exciting opportunity in our South San Francisco site to deploy AI to make a difference for patients suffering from debilitating diseases by working in a highly collaborative and energetic team in a startup environment with short communication lines across functions and departments.
Requirements
What will you be doing?
Traits we believe make a strong candidate:
Leveling Guidelines:
Benefits
At Frontier, we strive to build a diverse and equitable workplace. The salary range for this role is $134,840 - $158,900. Compensation for the role will depend on a number of factors, including candidates' qualifications, skills, competencies and experience. Frontier offers a competitive total rewards package which includes healthcare coverage, 401k and a broad range of other benefits.
This compensation and benefits information is based on Frontier's knowledge as of the date of publication, and may be modified in the future.

Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.